Cassidy Bio

Executive Summary

Cassidy Bio is an Israeli AI-driven platform that accelerates therapeutic gene-editing design using a genomic foundation model trained on massive human genomic data. Its technology predicts guide RNA efficacy, safety, and repair outcomes, enabling rapid, patient-specific CRISPR and base-editing strategies for rare and complex diseases. Founded in 2024 and based in Tel Aviv, the company operates at the intersection of artificial intelligence and gene therapy, targeting indications in rare diseases, hematology, and oncology. As a platform-stage private company, Cassidy Bio aims to streamline the traditionally slow and costly process of designing gene-editing therapies by providing in silico predictions that reduce reliance on extensive lab work. Despite being early-stage with no disclosed funding or valuation, its approach has the potential to significantly lower the barrier for developing CRISPR-based treatments, particularly for conditions with high unmet need. The company's success will depend on validation through partnerships or preclinical data, but its novel use of a genomic foundation model positions it as a promising player in the gene-editing space. The potential impact of Cassidy Bio's platform lies in its ability to democratize and expedite gene-editing design, making personalized therapies more accessible. By leveraging large-scale genomic data, the platform can identify optimal guide RNAs more accurately, reducing off-target effects and improving therapeutic safety. The company is currently in the platform development stage and likely seeking early funding or strategic collaborations to advance its technology. If successful, Cassidy Bio could become a key enabler for biopharma companies pursuing gene-editing programs, particularly in rare genetic disorders where patient-specific designs are crucial. The company's future will hinge on its ability to demonstrate platform utility through high-profile partnerships or published validation studies.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Round60% success
• Q1 2027Partnership with Major Biopharma for Gene-Editing Programs40% success
• H1 2026Publication of Platform Validation in Peer-Reviewed Journal50% success